The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.
R. Dienstmann
No relevant relationships to disclose
A. W. Tolcher
Consultant or Advisory Role - AbGenomics International (U); AbGenomics International (U); Abraxis BioScience (U); Abraxis BioScience (U); Actavis (U); Actavis (U); Adnexus (U); Adnexus (U); Ambit BioSciences (U); Ambit BioSciences (U); Amgen (U); Amgen (U); ARIAD (U); ARIAD (U); Arresto (U); Arresto (U); Astellas Pharma (U); Astellas Pharma (U); Bayer (U); Bayer (U); Biogen Idec (U); Biogen Idec (U); Chemokine (U); Chemokine (U); Curis (U); Curis (U); Dendreon (U); Dendreon (U); Dicerna (U); Dicerna (U); Endo Pharmaceuticals (U); Endo Pharmaceuticals (U); Exelixis (U); Exelixis (U); FivePrime (U); FivePrime (U); Genentech (U); Genentech (U); Geron (U); Geron (U); GlaxoSmithKline (U); GlaxoSmithKline (U); HUYA Bioscience International (U); HUYA Bioscience International (U); Insert Therapeutics (U); Insert Therapeutics (U); Intellikine (U); Intellikine (U); Johnson & Johnson (U); Johnson & Johnson (U); Merck (U); Merck (U); Nektar (U); Nektar (U); Novartis (U); Novartis (U); Ortho Biotech (U); Ortho Biotech (U); Otsuka (U); Otsuka (U); Pfizer (U); Pfizer (U); ProNAi (U); ProNAi (U); Regeneron (U); Regeneron (U); Sanofi (U); Sanofi (U); Santaris (U); Santaris (U); Spectrum Pharmaceuticals (U); Spectrum Pharmaceuticals (U); Spectrum Pharmaceuticals (U); Spectrum Pharmaceuticals (U); SuperGen (U); SuperGen (U); Vaccinex (U); Vaccinex (U); Veeda Oncology (U); Veeda Oncology (U)
Honoraria - AbGenomics International; AbGenomics International; Adnexus; Adnexus; Ambit BioSciences; Ambit BioSciences; ARIAD; ARIAD; Astellas Pharma; Astellas Pharma; Bayer; Bayer; Biogen Idec; Biogen Idec; Dendreon; Dendreon; Endo Pharmaceuticals; Endo Pharmaceuticals; Enzon; Enzon; Exelixis; Exelixis; FivePrime; FivePrime; Genentech; Genentech; Geron; Geron; GlaxoSmithKline; GlaxoSmithKline; Intellikine; Intellikine; Johnson & Johnson; Johnson & Johnson; Merck; Merck; Nektar; Nektar; Otsuka; Otsuka; Pfizer; Pfizer; Regeneron; Regeneron; Sanofi ; Sanofi ; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Symphogen; Symphogen
Research Funding - Abbott Laboratories; Abbott Laboratories; Adnexus; Adnexus; Ambit BioSciences; Ambit BioSciences; Amgen; Amgen; ArQule; ArQule; Array BioPharma; Array BioPharma; Arresto; Arresto; Astellas Pharma; Astellas Pharma; AVEO; AVEO; Azaya Therapeutics; Azaya Therapeutics; Azaya Therapeutics; Azaya Therapeutics; Bayer; Bayer; Biogen Idec; Biogen Idec; BiPar Sciences; BiPar Sciences; Bristol-Myers Squibb; Bristol-Myers Squibb; Calando; Calando; Centocor Ortho Biotech; Centocor Ortho Biotech; Coronado Biosciences; Coronado Biosciences; Cougar Biotechnology; Cougar Biotechnology; Cyclacel; Cyclacel; Cylene; Cylene; Daiichi Sankyo; Daiichi Sankyo; Dendreon; Dendreon; Enzon; Enzon; Exelixis; Exelixis; FivePrime; FivePrime; Genentech; Genentech; Genta; Genta; GlaxoSmithKline; GlaxoSmithKline; Hana BioSciences; Hana BioSciences; Immunogen; Immunogen; Lilly; Lilly; Merck; Merck; Merrimack; Merrimack; MethylGene; MethylGene; Millennium; Millennium; Myrexis; Myrexis; Myriad Genetics; Myriad Genetics; Nektar; Nektar; Nerviano; Nerviano; OncoMed; OncoMed; Onyx; Onyx; PharmaMar; PharmaMar; Proacta; Proacta; ProNAi; ProNAi; Roche; Roche; Sanofi ; Sanofi ; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; SuperGen; SuperGen; Symphogen; Symphogen; Vaccinex; Vaccinex
K. P. Papadopoulos
Research Funding - Symphogen
D. W. Rasco
Research Funding - Symphogen
J. Tabernero
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; ImClone Systems; Merck Serono
I. Brana
No relevant relationships to disclose
A. Piera
No relevant relationships to disclose
N. J. Skartved
No relevant relationships to disclose
H. Aladdin
Employment or Leadership Position - Symphogen; Symphogen
J. Petersen
Employment or Leadership Position - Symphogen; Symphogen
A. Patnaik
Research Funding - Symphogen